Results 181 to 190 of about 15,919 (234)

Is Routine Interruption of Direct Oral Anticoagulants Necessary during Colorectal Endoscopic Mucosal Resection and Hot Snare Polypectomy? A Multicenter Propensity-Matched Study. [PDF]

J Gastroenterol Hepatol
Okagawa Y, Sato M, Hirakawa M, Miura S, Hayasaka N, Tomita Y, Ameda S, Omori G, Oiwa S, Sakurada A, Abe T, Minami S, Sumiyoshi T, Nagaoka Y, Hisai H, Katsuki S, Takada K.   +16 more
europepmc   +1 more source

Accuracy of Direct Oral Anticoagulants (DOAC) Dipstick in patients treated preoperatively with DOAC

Vassart, Julie; id_orcid 0009-0004-2512-7494, Tafur, Alfonso, Boucher, Anne-Yseult, Morimont, Laure, Walenga, Jeanine, Harenberg, Job F., Douxfils, Jonathan; id_orcid 0000-0002-7644-5298   +6 more
openaire   +1 more source

Clotting Test Results Correlate Better With DOAC Concentrations When Expressed as a “Correction Ratio”; Results Before/After Extraction With the DOAC Stop Reagent

Thrombosis Research, 2019
INTRODUCTION: Clotting test results are currently not useful for estimating direct oral anti-coagulant (DOAC) concentrations because baseline results vary. DOAC Stop is a DOAC extracting agent with no effect on clotting factors.
Sarah Lessire, François Mullier, Jonathan Douxfils   +2 more
exaly   +2 more sources

DOAC in the Treatment of Cancer-Associated Venous Thromboembolism: A Retrospective Cohort Study Beyond the Guidelines

Journal of Cancer Research and Clinical Oncology, 2023
Background: The emerging use of direct oral anticoagulants (DOAC) in the management of cancer-associated venous thromboembolism (CAT) is significantly improving therapeutic adherence and quality of life.
Luca Dalle Carbonare, Mattia Cominacini, Roberto Ciresa   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

MHRA DOAC safety reminder

Drug and Therapeutics Bulletin, 2020
Abstract Review of: Medicines and Healthcare products Regulatory Agency. Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents.
openaire   +2 more sources

Gender-Associated Variation in DOAC Levels

Clinical Laboratory, 2023
Direct oral anticoagulants (DOAC) such as Xa inhibitors rivaroxaban (riva) and apixaban (apix) are increasingly replacing Vitamin K antagonists in prophylaxis and treatment of venous thromboembolism (VTE). Measurements of DOAC plasma levels may be necessary in certain clinical conditions to determine the further dosage.
Anja, Moldenhauer, Peter, Hellstern, Till, Hoffmann, Johannes C, Fischer   +3 more
openaire   +2 more sources

DOAC dosing in renal impairment

Drug and Therapeutics Bulletin, 2019
Dabigatran was the first direct acting oral anticoagulant (DOAC) launched in the UK and has been in clinical use for over 10 years. Since then, ▾rivaroxaban, apixaban and ▾edoxaban have been marketed, and between them the four DOACs account for over 800 000 prescriptions per month in England.1 DOACs provide some advantages over warfarin, including a ...
openaire   +2 more sources

Performance of HAS-BLED and DOAC Scores to Predict Major Bleeding Events in Atrial Fibrillation Patients Treated With Direct Oral Anticoagulants: A Report From a Prospective European Observational Registry [PDF]

European Journal of Internal Medicine
Background: The DOAC score has been recently proposed for bleeding risk stratification of patients with atrial fibrillation treated with direct oral anticoagulants (DOAC).
Bernadette Corica, Giulio Francesco Romiti, Marco Vitolo   +2 more
exaly   +3 more sources

Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment

CNS Drugs, 2023
The use of direct oral anticoagulants (DOACs) is increasing because of their superior efficacy and safety compared with vitamin K antagonists. Pharmacokinetic drug interactions, particularly those involving cytochrome P450- mediated metabolism and P-glycoprotein transport, significantly affect the efficacy and safety of DOACs.
Rachel Goldstein, Aviya R. Jacobs, Lana Zighan, Naomi Gronich, Meir Bialer, Mordechai Muszkat   +5 more
openaire   +2 more sources

DOACS in women: pros and cons

Thrombosis Research, 2019
The recent approval of direct-acting oral anticoagulants (DOAC) for long-term anticoagulation in atrial fibrillation and venous thromboembolism resulted in a rapid implementation of these new drugs into daily care. Although DOAC dosing is similar for women and men and, overall, results in comparable outcomes, sex specific issues need to be considered ...
openaire   +3 more sources